Creoptix

Creoptix2022-09-02T08:20:13+01:00

COMPANY INFO

MEDTECH – Switzerland

EXIT 2022

Creoptix

COMPANY PROFILE

Creoptix founded in 2009 is based in Wädenswil, Switzerland. The company is specialized in optical instruments and consumables for the label-free analysis of molecular interactions at best-in-class sensitivity for life science research and the drug discovery industry. Creoptix is revolutionizing the study of label-free molecular interactions and changing the world of drug discovery.

NEWS

  • CREOPTIX

Malvern Panalytical expands pharmaceutical drug development solutions through the acquisition of Creoptix

January 11th, 2022|

  • Creoptix

Creoptix launches new way of measuring kinetics to accelerate drug discovery

February 2nd, 2021|

Domainex invests in the Creoptix WAVEdelta to strengthen its fragment-based drug discovery platform

January 12th, 2021|

Swiss start-ups drive research around Covid-19

May 27th, 2020|

Microfluidics mastery earns Switzerland’s Creoptix $8m Series C

October 4th, 2019|

Creoptix raises CHF8m Series C financing round

September 30th, 2019|